Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 8/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238803 | 0.93 | ESRRG (0.48) | ESRRGHTR7MCHR1KDM4EALDH1A1 | |
| SCHEMBL4233332 | 0.82 | ESRRG (0.60) | ESRRGHTR7NOS3NOS1NOS2 | |
| SCHEMBL4235481 | 0.80 | DRD2 (0.45) | ESRRGMCHR1MCHR2KDM4EALDH1A1 | |
| SCHEMBL14594152 | 0.80 | HTR7 (0.66) | ESRRGHTR7NOS3NOS1NOS2 | |
| SCHEMBL4228624 | 0.77 | KDM4E (0.47) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4236438 | 0.77 | CNR2 (0.48) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL30969220 | 0.76 | ESRRG (0.54) | ESRRGHTR7NOS3NOS1NOS2 | |
| SCHEMBL23927863 | 0.75 | HTR7 (0.61) | ESRRGHTR7NOS3NOS1NOS2 | |
| SCHEMBL16705820 | 0.75 | HTR7 (0.63) | ESRRGHTR7NOS3NOS1NOS2 | |
| SCHEMBL4263907 | 0.75 | HTR7 (0.54) | ESRRGHTR7NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ESRRG 957/4885HTR7 144/4885MCHR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.